Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Sponsor

Bristol-Myers Squibb

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT01838512

Official Title: Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

First Posted : April 24, 2013

Click here to see details on ClinicalTrials.gov

---

Locations

United States, Alabama

United States, Arizona

United States, California

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kentucky

United States, Louisiana

United States, Minnesota

United States, Mississippi

United States, Missouri

United States, Montana

United States, Nebraska

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, South Carolina

United States, Tennessee

United States, Texas

United States, Washington

Canada, Ontario

Europe

United Kingdom

France

Germany

Italy